Targeted exonic next generation sequencing for the molecular diagnosis and cell free tumor DNA analysis as screening method for patients with DLBCL. (Q3141608): Difference between revisions
Jump to navigation
Jump to search
(Created claim: summary (P836): The aim of this Project is to Characterise the genetic profile of a selected series of diffuse large B cell lymphoma patient samples by means of targeted exonic next generation sequencing. Diagnostic samples (tumor and normal DNA) from patients involved in three different clinical trials and a retrospective series of plasmablastic lymphoma cases will be analysed using a targeted next generation sequencing approach, in order to identify markers a...) |
(Changed label, description and/or aliases in en: translated_label) |
||
| label / en | label / en | ||
Targeted exonic next generation sequencing for the molecular diagnosis and cell free tumor DNA analysis as screening method for patients with DLBCL. | |||
Revision as of 13:17, 12 October 2021
Project Q3141608 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Targeted exonic next generation sequencing for the molecular diagnosis and cell free tumor DNA analysis as screening method for patients with DLBCL. |
Project Q3141608 in Spain |
Statements
40,750.0 Euro
0 references
81,500.0 Euro
0 references
50.0 percent
0 references
1 January 2017
0 references
31 March 2020
0 references
FUNDACION INSTITUTO DE INVESTIGACION MARQUES DE VALDECILLA (IDIVAL)
0 references
43°27'43.34"N, 3°48'35.89"W
0 references
39075
0 references
The aim of this Project is to characterize the genetic profile of a selected series of diffuse large B cell lymphoma patient samples by means of targeted exonic next generation sequencing. Diagnostic samples (tumor and normal DNA) from patients involved in three different clinical trials and a retrospective series of plasmablastic lymphoma cases will be analyzed using a targeted next generation sequencing approach, in order to identify markers associated with response to therapy. The samples are provided by three clinical trials from GELTAMO group (GEL-BRCAP21 (Nº EudraCT: 2012-005138-12), GEL-RCOMP 2013 (Nº EudraCT: 2013-001065-17) and LR-ESHAP (Nº EudraCT: 2010-018463-41). Plasmablastic lymphomas cases are obtained from biobank Valdecilla. Targeted exonic next generation sequencing will be performed using both normal and tumor DNA from patients. Library generation will be performed using a customized kit, developed in collaboration with Illumina, for this purpose. Sequencing will be done with MiSeq (Illumina) platform. In addition to his, we aim to develop a protocol for the accurate and sensitive detection of somatic mutations in the plasma of patients at diagnosis (circulating cell free tDNA) by means of digital PCR. This test may have an application in the screening and follow of patients with a suspicion or previously treated DLBCL, respectively. Next generation sequencing will also be used to explore the T cell repertoire in a selection of tumor samples with DLBCL and study its relationship with the mutational profiles, protein expression profiles and clinical outcome. (Spanish)
0 references
The aim of this Project is to Characterise the genetic profile of a selected series of diffuse large B cell lymphoma patient samples by means of targeted exonic next generation sequencing. Diagnostic samples (tumor and normal DNA) from patients involved in three different clinical trials and a retrospective series of plasmablastic lymphoma cases will be analysed using a targeted next generation sequencing approach, in order to identify markers associated with response to therapy. The samples are provided by three clinical trials from GELTAMO group (GEL-BRCAP21) 2012-005138-12), GEL-RCOMP 2013 (EurdraCT No: 2013-001065-17) and LR-ESHAP (EurdraCT No: 2010-018463-41). Plasmablastic lymphomas cases are obtained from biobank Valdecilla. Targeted exonic next generation sequencing will be performed using both normal and tumor DNA from patients. Library generation will be performed using a customised kit, developed in collaboration with Illumina, for this purpose. Sequencing will be done with MiSeq (Illumina) platform. In addition to his, we aim to develop a protocol for the accurate and sensitive detection of somatic mutations in the plasma of patients at diagnosis (circulating cell free TDNA) by means of digital PCR. This test may have an application in the screening and follow of patients with a suspicion or previously treated DLBCL, respectively. Next generation sequencing will also be used to explore the T cell repertoire in a selection of tumor samples with DLBCL and study its relationship with the mutational profiles, protein expression profiles and clinical outcome. (English)
12 October 2021
0 references
Santander
0 references
Identifiers
PI16_01397
0 references